Getting the best treatment for your Parkinson’s Disease

Leila Montaser Kouhsari, MD, PhD
Assistant Clinical Professor of Neurology
and Neurological Sciences
Division of Movement Disorders
Stanford University
Parkinson’s Disease

Substantia Nigra
Parkinsonism comprises four cardinal motor features

- **Bradykinesia** (slow and small movements). Reduced blink, face expression, and gesturing. Soft voice. Difficulty getting out of chair, shuffling steps, reduced arm swing, freezing
- **Tremor** (usually resting) “pill rolling”, often involves thumb
- **Rigidity** (different from spasticity)
- **Postural changes.** Imbalance, falls; stooped flexed posture
Common non-motor symptoms in Parkinson’s Disease

<table>
<thead>
<tr>
<th>Early non-motor symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive impairment</td>
</tr>
<tr>
<td>Constipation</td>
</tr>
<tr>
<td>Anosmia</td>
</tr>
<tr>
<td>Sleep disorders (RBD)</td>
</tr>
<tr>
<td>Depression/Apathy</td>
</tr>
<tr>
<td>Anxiety</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Late non-motor symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dementia</td>
</tr>
<tr>
<td>Psychosis</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
</tr>
<tr>
<td>Dysphagia</td>
</tr>
</tbody>
</table>
Available treatments for motor symptoms in PD

International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson’s Disease

Fox et al. 2018
Treatment of motor symptoms

- No effective neuroprotective agent
Treatment of motor symptoms

- Monotherapy (efficacious):
  - Carbidopa-Levodopa (Sinemet)

Oertel and Schulz 2016
Does early treatment with Levodopa increase motor complications?

Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease

Constant V.M. Verschuur, M.D., Sven R. Suwijn, M.D., Judith A. Boel, Ph.D., Bart Post, M.D., Ph.D., Bas R. Bloem, M.D., Ph.D., Johannes J. van Hilten, M.D., Ph.D., Teus van Laar, M.D., Ph.D., Gerrit Tissingh, M.D., Ph.D., Alexander G. Munts, M.D., Ph.D., Guenther Deuschl, M.D., Anthony E. Lang, M.D., Marcel G.W. Dijkgraaf, Ph.D., et al., for the LEAP Study Group®

Verschuur et al. 2019
Leap study

- Multicenter, double-blind study in early PD
- Patients divided into Early or delayed group
- Early group: on Carbidopa/levodopa 25/100 mg TID at baseline
- DELAYED group: Carbidopa/levodopa started at 40 weeks
- Investigated response to therapy at the end of the 80 weeks

Verschuur et al. 2019
Leap study

- Primary outcome: no significant motoric difference between the two groups at the end of 80 weeks

- Secondary outcome: no significant differences in motor fluctuations, dyskinesia, depression or cognitive scales

- Weeks 4 to 40: symptomatic benefit of Carbidopa-Levodopa
- Weeks 44 to 80: absence of disease-modifying effect of Carbidopa-Levodopa

Verschuur et al. 2019
Are motor complications primarily related to the duration of levodopa therapy or disease-related factors?

Motor fluctuations and dyskinesias are not associated with the duration of levodopa therapy, but rather with longer disease duration and higher levodopa daily dose.

Hauser et al. 2007
Available preparations of Carbidopa-Levodopa

- Carbidopa-Levodopa immediate release (Sinemet)
- Orally dissolving (Parcopa)
- Carbidopa-Levodopa controlled release (Sinemet CR)
- Combination with entacapone (Stalevo)
- IR/CR (Rytary)
- Levodopa intestinal gel (Duopa): delivered directly to the small intestine via a J tube, continuously released during the day, 47% complications

Fernandez et al. 2015; Stocchi et al. 2010; Koller et al. 1999
Under development preparations of Carbidopa-Levododopa

Neuroderm:
- Continuous subcutaneous infusion of liquid Levodopa/Carbidopa (60/7.5 mg/mL) through a non-surgical mini-pump system
- Causing a stable blood level of Levodopa
- Low dose of up to 360 mg levodopa infused via one infusion site
- High dose of up to 720 mg levodopa infused via two infusion sites
- Reduction in off-time and on-time dyskinesia

Giladi et al. 2015; Kieburtz et al. 2016; Stocchi et al. 2019
Inhalational Levodopa powder (Inbrija)

- FDA approved in 12/2018, 2 caps per dose
- SPAN-PD, multicenter, double-blind and placebo-controlled
- PD patients with >=2 h off-time/day
- 42mg, 84mg or placebo, up to 5 x day, 12-week study
- Significant change in UPDRS after 30 min (low and high dose), and after 60 min (high dose)
- Side effects cough, throat irritation, sputum discoloration and URI
- No change in PFT

Lewitt et al. 2019
Treatment of motor symptoms

- Monotherapy (efficacious):
  - Levodopa-Carbidopa
  - Dopamine agonists (Pramipexole, Ropinirole, Rotigotine)

Fox et al. 2018
Dopamine agonist vs Levodopa

Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease

Parkinson Study Group CALM Cohort Investigators, Arch neurology 2009

Ten-Year Follow-Up of Parkinson’s Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa

Hauser et al., Movement Disorders 2007
Dopamine agonists side effects

Impulse control disease (ICD):
- Pathological gambling
- Compulsive eating
- Compulsive shopping
- Hypersexuality

- 5-years cumulative incidence of ICDs 51.5%

Rabinak and Nirenberg 2010; Corvol et al. 2018
Dopamine agonists side effects

- Excessive daytime sleepiness
- Hallucinations
- Orthostatic hypotension
- Pedal edema
- They can be addictive; 1/3 of patients can have withdrawal symptoms even when the tapering is done very slowly
- These symptoms are subtle, including panic attack, agitation, fatigue, dysphoria, sleep disturbance, suicidality, restlessness, and generalized pain

Rabinak and Nirenberg 2010
Treatment of motor symptoms

- No effective neuroprotective agent
- Monotherapy (efficacious):
  - Levodopa-Carbidopa
  - Dopamine agonists: (Pramipexole, Ropinirole, Rotigotine)
  - MAO-B inhibitors (Selegiline, Rasagiline)

Fox et al. 2018
MAO-B inhibitors

• Extend half-life of dopamine by inhibiting its breakdown
• **Selegiline** metabolized to levoamphetamine
  - Not suitable to be given late during the day since can cause insomnia
• **Rasagiline** does not have amphetamine metabolites
• **Safinamide (Xadago)**
  - Potent, highly selective reversible MAO-B inhibitor
  - Blocks voltage-dependent Na and Ca channels
  - Reduces neuronal glutamate release
  - *Ineffective as monotherapy but has shown to increase on-time* * 

* Schapira et al. 2017
Treatment of motor symptoms

- No effective neuroprotective agent
- Monotherapy (efficacious):
  - Levodopa-Carbidopa
  - Dopamine agonists (Pramipexole, Ropinirole, Rotigotine)
  - MAO-B inhibitors (Selegiline, Rasagiline)
  - **Amantadine (likely efficacious)**

Fox et al. 2018
Amantadine

- NMDA and nicotinic antagonist
- Need to be careful to prescribe it in the elderly and patients with kidney disease
- Side effects: constipation, dry mouth, dizziness/orthostatic hypotension, leg swelling, nausea, livedo reticularis
Newer versions of Amantadine

- **Gocoveri** (Extended-release capsules):
  - Once at night (placebo-controlled trial)*
  - Decreases levodopa-associated dyskinesia and off-time
  - Costly

- **Osmolex** (The combination of IR and ER):
  - Not specifically approved for dyskinesia
  - Less expensive than Gocoveri

* Pahwa et al., 2017, Oertel et al. 2017
Treatment of motor symptoms

- No effective neuroprotective agent
- Monotherapy (efficacious):
  - Levodopa-Carbidopa
  - Dopamine agonists: (pramipexole, Ropinirole, Rotigotine)
  - MAO-B inhibitors: (Selegiline, Rasagiline)
  - Amantadine (likely efficacious)
  - **Anticholinergic (likely efficacious):** can help tremor, has side effects so reserved for young patients

Fox et al. 2018
Motor fluctuations (efficacious)

- Dopamine agonists: (Pramipexole, Ropinirole, Rotigotine)
- Levodopa extended-release
- Levodopa intestinal gel (Duopa)
- COMT inhibitors (Entacapone, Tolcapone, Opicapone)

Fox et al. 2018
COMT inhibitors

- Prolong the effect of Levodopa by inhibiting catechol-O-methyltransferase
- Entacapone (Comtan): given with each dose of Sinemet, peripheral inhibition of COMT
- Tolcapone: given 3 time a day, peripheral and central inhibition of COMT
  - Fulminate hepatoxicity reported in 4 patients with 3 deaths
  - Liver enzyme monitoring is needed
- FDA approved Opicapone (Ongentys) to use in April 2020
  - Peripheral COMT inhibitor, once daily
  - Increases daily on-time *
  - Non-inferior to (Entacapone)

* Less et al. 2017
Motor fluctuations (efficacious)

- Dopamine agonists: (Pramipexole, Ropinirole, Rotigotine)
- Levodopa extended-release
- Levodopa intestinal gel (Duopa)
- COMT inhibitors (Entacapone, Tolcapone, Opicapone)
- Adenosine A2A antagonist (Istradefylline (Nourianz)): (likely efficacious)

Fox et al., 2018
Motor fluctuations (efficacious):

- Dopamine agonists (Pramipexole, Ropinirole, Rotigotine)
- Levodopa extended-release
- Levodopa intestinal gel (Duopa)
- COMT inhibitors (Entacapone, Tolcapone, Opicapone):
- MAO-B inhibitors (Rasagiline, Safinamide)
- Adenosine A2A antagonist (Istradefylline): likely efficacious
- Zonisamide: low dose 50 mg/day (Murata et al. 2015)
Motor fluctuations (efficacious):

- Dopamine agonists (Pramipexole, Ropinirole, Rotigotine)
- Levodopa extended-release
- Levodopa intestinal gel (Duopa)
- COMT inhibitors (Entacapone, Tolcapone, Opicapone):
- MAO-B inhibitors (Rasagiline, Safinamide)
- Adenosine A2A antagonist (Istradefylline): likely efficacious
- Zonisamide: low dose 50 mg/day (Murata et al. 2015)
- Apomorphine

Fox et al. 2018
Apomorphine

- It is not an opiate, highly potent, a nonselective dopamine agonist
- Can not be used orally
- Subcutaneous injection (Apokyn) is FDA approved in 2004 for acute motor offs but found to be hard to use during off-time
- Side effects: potent emetic (needs to be premedicated with antiemetics), orthostatic hypotension
- Apomorphine film for sublingual use (Kynmobi) approved in 2020: up to five times a day, at doses ranging from 10 mg to 30 mg, potent and fast-acting *

*Hauser et al. 2016
**Motor fluctuations (efficacious):**

- Dopamine agonists (Pramipexole, Ropinirole, Rotigotine)
- Levodopa extended-release
- Levodopa intestinal gel (Duopa)
- COMT inhibitors (Entacapone, Tolcapone, Opicapone): prolong the effect of levodopa
- MAO-B inhibitors (Rasagiline, Safinamide)
- Adenosine A2A antagonist (Istradefylline): likely efficacious
- Zonisamide: low dose 50 mg/day (Murata et al. 2015)
- Apomorphine
- **Deep Brain Stimulation (DBS)**

Fox et al. 2018
Dyskinesia (efficacious)

- Amantadine
- Levodopa gel intestinal infusions (likely efficacious)
- Clozapine
- Unilateral pallidotomy
- DBS

Fox et al. 2018
Treatment of PD as an adjunct in early or stable PD

- Dopamine agonists: (pramipexole IR, ER, ropinirole IR, rotigotine)
- MAO-B inhibitors: (Rasagiline, safinamide: non-efficacious)
- Anticholinergic (likely efficacious)
- Amantadine (likely efficacious)
- Zonisamide
- Adenosine A2A antagonist (Istradefylline (Nourianz)): non-efficacious
- COMT inhibitors (tolcapone: but risky so not useful, entacapone: non-efficacious)
Get Involved
We rely on the energy, skill and passion of our volunteers, advocates and fundraisers to make life better for people with Parkinson’s and advance research toward a cure.

Engage
• Moving Day
• Parkinson’s Revolution
• Educational Programs

Educate
• Aware in Care Ambassador
• Education Program Volunteer

Advise
• People with Parkinson’s Council
• Research Advocate
Moving Day San Francisco

Saturday, April 23rd
The Great Meadow at Fort Mason

www.MovingDaySanFrancisco.org for more info or to register!
Revolution San Francisco

- **February 26th**– Location TBD
- In-person, outdoor spin class (COVID safe)
- Appx 30 in-person riders plus virtual options

[www.PDRevolutionSF.org](http://www.PDRevolutionSF.org) for more info or to register!
We’re Here For You

Parkinson.org
Parkinson.org/California
Facebook.com/PFCalifornia

1-800-4PD-INFO
Helpline@Parkinson.org

GLennon@parkinson.org
415-963-0304